ANTX
AN2 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.37
−0.30%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.20
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.18
- EPS estimate
- -$0.24
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -14.2%
- Revenue beats (12Q)
- —
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.24 | -$0.18 | Beat 25.00% | — |
| May 11, 2026 | -$0.23 | -$0.29 | Miss -26.09% | — |
| Mar 17, 2026 | -$0.24 | -$0.29 | Miss -20.83% | — |
| Nov 12, 2025 | -$0.23 | -$0.31 | Miss -34.78% | — |
| Mar 25, 2025 | -$0.25 | -$0.25 | In line | — |
| Nov 9, 2023 | -$0.63 | -$0.65 | Miss -3.17% | — |
| Aug 10, 2023 | -$0.85 | -$0.81 | Beat 4.71% | — |
| May 11, 2023 | -$0.68 | -$0.79 | Miss -16.18% | — |
| Nov 9, 2022 | -$0.59 | -$0.59 | In line | — |
| Aug 11, 2022 | -$0.45 | -$0.53 | Miss -17.78% | — |
| Dec 31, 2021 | — | -$0.42 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026